Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion
Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27 Piramal Pharma expects to sustain mid-teen revenue growth…






